These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
437 related articles for article (PubMed ID: 26523025)
1. Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with Rheumatoid Arthritis in Remission: A CORRONA and NinJa Collaborative Cohort Study. Yoshida K; Radner H; Mjaavatten MD; Greenberg JD; Kavanaugh A; Kishimoto M; Matsui K; Okada M; Reed G; Saeki Y; Tohma S; Kremer J; Solomon DH J Rheumatol; 2015 Dec; 42(12):2238-46. PubMed ID: 26523025 [TBL] [Abstract][Full Text] [Related]
2. Low rates of biologic-free clinical disease activity index remission maintenance after biologic disease-modifying anti-rheumatic drug discontinuation while in remission in a Japanese multicentre rheumatoid arthritis registry. Yoshida K; Kishimoto M; Radner H; Matsui K; Okada M; Saeki Y; Solomon DH; Tohma S Rheumatology (Oxford); 2016 Feb; 55(2):286-90. PubMed ID: 26350484 [TBL] [Abstract][Full Text] [Related]
3. Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization registry. Narongroeknawin P; Chevaisrakul P; Kasitanon N; Kitumnuaypong T; Mahakkanukrauh A; Siripaitoon B; Katchamart W; Int J Rheum Dis; 2018 Jan; 21(1):170-178. PubMed ID: 28737837 [TBL] [Abstract][Full Text] [Related]
4. Effect of Concomitant Disease-modifying Antirheumatic Drugs and Methotrexate Administration Route on Biologic Treatment Durability in Rheumatoid Arthritis: OBRI Cohort Results. Lau AN; Thorne JC; Movahedi M; Rampakakis E; Cesta A; Li X; Couto S; Sampalis J; Bombardier C; J Rheumatol; 2019 Aug; 46(8):874-886. PubMed ID: 30988121 [TBL] [Abstract][Full Text] [Related]
5. Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study. Hashimoto M; Furu M; Yamamoto W; Fujimura T; Hara R; Katayama M; Ohnishi A; Akashi K; Yoshida S; Nagai K; Son Y; Amuro H; Hirano T; Ebina K; Uozumi R; Ito H; Tanaka M; Ohmura K; Fujii T; Mimori T Arthritis Res Ther; 2018 Aug; 20(1):165. PubMed ID: 30075810 [TBL] [Abstract][Full Text] [Related]
6. Predictors of long-term clinical remission in rheumatoid arthritis. Fornaro M; Cacciapaglia F; Lopalco G; Venerito V; Iannone F Eur J Clin Invest; 2021 Feb; 51(2):e13363. PubMed ID: 32725883 [TBL] [Abstract][Full Text] [Related]
7. Predictors of successful discontinuation of biologic and targeted synthetic DMARDs in patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review. Schlager L; Loiskandl M; Aletaha D; Radner H Rheumatology (Oxford); 2020 Feb; 59(2):324-334. PubMed ID: 31325305 [TBL] [Abstract][Full Text] [Related]
8. Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry. Kavanaugh A; Lee SJ; Curtis JR; Greenberg JD; Kremer JM; Soto L; Etzel CJ; Cox V; Yoshida K; Reed GW; Solomon DH Ann Rheum Dis; 2015 Jun; 74(6):1150-5. PubMed ID: 25471471 [TBL] [Abstract][Full Text] [Related]
9. Potential benefits of biologics on stroke and mortality in patients with rheumatoid arthritis: A nationwide population-based cohort study in Taiwan. Tang CH; Yu F; Huang CY; Chen DY Int J Rheum Dis; 2019 Aug; 22(8):1544-1552. PubMed ID: 31240863 [TBL] [Abstract][Full Text] [Related]
10. Prediction of disease flare by biomarkers after discontinuing biologics in patients with rheumatoid arthritis achieving stringent remission. Kameda H; Hirata A; Katagiri T; Takakura Y; Inoue Y; Takenaka S; Ito H; Mizushina K; Ogura T Sci Rep; 2021 Mar; 11(1):6865. PubMed ID: 33767314 [TBL] [Abstract][Full Text] [Related]
11. Predictors of biologic discontinuation due to insufficient response in patients with rheumatoid arthritis who achieved clinical remission with biologic treatment: A multicenter observational cohort study. Asai S; Fujibayashi T; Oguchi T; Hanabayashi M; Hayashi M; Matsubara H; Ito T; Yabe Y; Watanabe T; Hirano Y; Kanayama Y; Kaneko A; Kato T; Takagi H; Takahashi N; Funahashi K; Takemoto T; Asai N; Watanabe T; Ishiguro N; Kojima T Mod Rheumatol; 2018 Mar; 28(2):221-226. PubMed ID: 28701065 [TBL] [Abstract][Full Text] [Related]
12. Relapse in rheumatoid arthritis patients undergoing dose reduction and withdrawal of biologics: are predictable factors more relevant than predictive parameters? An observational prospective real-life study. Vittecoq O; Desouches S; Kozyreff M; Nicolau J; Pouplin S; Rottenberg P; Sens N; Lequerre T; Avenel G BMJ Open; 2019 Dec; 9(12):e031467. PubMed ID: 31857303 [TBL] [Abstract][Full Text] [Related]
13. Ultrasound-detected bone erosion is a relapse risk factor after discontinuation of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis whose ultrasound power Doppler synovitis activity and clinical disease activity are well controlled. Kawashiri SY; Fujikawa K; Nishino A; Okada A; Aramaki T; Shimizu T; Umeda M; Fukui S; Suzuki T; Koga T; Iwamoto N; Ichinose K; Tamai M; Mizokami A; Nakamura H; Origuchi T; Ueki Y; Aoyagi K; Maeda T; Kawakami A Arthritis Res Ther; 2017 May; 19(1):108. PubMed ID: 28545509 [TBL] [Abstract][Full Text] [Related]
14. Dose down-titration of biological disease-modifying antirheumatic drugs in daily clinical practice: Shared decision-making and patient treatment preferences in Japanese patients with rheumatoid arthritis. Komiya T; Takase-Minegishi K; Sakurai N; Nagai H; Hamada N; Soejima Y; Sugiyama Y; Tsuchida N; Kunishita Y; Kishimoto D; Kobayashi K; Kamiyama R; Yoshimi R; Kirino Y; Ohno S; Nakajima H Int J Rheum Dis; 2019 Nov; 22(11):2009-2016. PubMed ID: 31515933 [TBL] [Abstract][Full Text] [Related]
15. Tapering and Discontinuation of Biologics in Patients with Psoriatic Arthritis with Low Disease Activity. Ye W; Tucker LJ; Coates LC Drugs; 2018 Nov; 78(16):1705-1715. PubMed ID: 30341684 [TBL] [Abstract][Full Text] [Related]
16. Identifying markers of sustained remission in rheumatoid arthritis patients on long-term tapered biological disease-modifying antirheumatic drugs. Valor L; Garrido J; Martínez-Estupiñán L; Hernández-Flórez D; Janta I; López-Longo FJ; Monteagudo I; González CM; Naredo E Rheumatol Int; 2018 Aug; 38(8):1465-1470. PubMed ID: 29915991 [TBL] [Abstract][Full Text] [Related]
17. Predictors and causes of first-line biologic agent discontinuation in rheumatoid arthritis: data from Reuma.pt. Gomes JL; Sepriano A; Eusébio M; Serra S; Fonseca JE; Saavedra MJ; Cunha-Miranda L; Silva C; Bernardes M; Rosa-Gonçalves D; Costa J; Castelão W; Branco JC; Santos MJ Acta Reumatol Port; 2019; 44(1):57-64. PubMed ID: 31249276 [TBL] [Abstract][Full Text] [Related]
18. Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis. Henaux S; Ruyssen-Witrand A; Cantagrel A; Barnetche T; Fautrel B; Filippi N; Lukas C; Raffeiner B; Rossini M; Degboé Y; Constantin A Ann Rheum Dis; 2018 Apr; 77(4):515-522. PubMed ID: 29187350 [TBL] [Abstract][Full Text] [Related]
19. Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission. El Miedany Y; El Gaafary M; Youssef S; Ahmed I; Bahlas S; Hegazi M; Nasr A Clin Rheumatol; 2016 Dec; 35(12):2915-2923. PubMed ID: 27658417 [TBL] [Abstract][Full Text] [Related]
20. Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study. Ebina K; Hashimoto M; Yamamoto W; Hirano T; Hara R; Katayama M; Onishi A; Nagai K; Son Y; Amuro H; Yamamoto K; Maeda Y; Murata K; Jinno S; Takeuchi T; Hirao M; Kumanogoh A; Yoshikawa H Arthritis Res Ther; 2019 Apr; 21(1):91. PubMed ID: 30971306 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]